Atkins MB et al. DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): A phase III trial—ECOG-ACRIN EA6134. ASCO Monthly Plenary Series 2021;Abstract 356154.

Dummer R et al. Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. ASCO 2021;Abstract 9507.

Dummer R et al. Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma. ESMO 2022;Abstract 786O.

Gogas H et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Eur J Cancer 2021;152:116-28. Abstract

Hodi FS et al. Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. ASCO 2022;Abstract 9522.

Long GV et al. Relatlimab and nivolumab vs nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). ASCO Plenary Series 2022;Abstract 360385.

Tawbi HA et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022;386(1):24-34. Abstract